The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab

被引：7
|
作者：
Plasencia, Ch [1 ]
Pascual-Salcedo, D. [2 ]
Alcocer, P. [1 ]
Bonilla, M. G. [1 ]
Villalba, A. [1 ]
Peiteado, D. [1 ]
Arribas, F. [2 ]
Diez, J. [3 ]
Lopez-Casla, M. T. [2 ]
Martin-Mola, E. [1 ]
Balsa, A. [1 ]
机构：
[1] Paz Univ Hosp Idipaz, Dept Rheumatol, Paseo Castellana 261, Madrid 28046, Spain
[2] Paz Univ Hosp Idipaz, Immunol Unit, Madrid, Spain
[3] Paz Univ Hosp Idipaz, Stat Dept, Madrid, Spain
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷 / 11期
关键词：
Anti-TNF; Rheumatoid Arthritis; Treatment; IMMUNOGENICITY;
D O I：
10.1136/annrheumdis-2013-203353
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1888 / 1890
页数：3
相关论文
共 50 条
  • [1] Predictors of formation of antibodies to infliximab (ATI) and secondary loss of response in IBD patients treated with infliximab
    Ungar, B.
    Kopylov, U.
    Yavzori, M.
    Fudim, E.
    Picard, O.
    Lahat, A.
    Avidan, B.
    Lang, A.
    Weiss, B.
    Chowers, Y.
    Eliakim, R.
    Ben-Horin, S.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S45 - S45
  • [2] PILOT STUDY: SELECTIVE DEGLYCOSYLATION OF TERMINAL SIALIC ACID ON INFLIXIMAB INCREASES BINDING OF ANTIBODIES TO INFLIXIMAB (ATI) IN ATI-POSITIVE INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS
    Zhang, Bing
    Hwang, Caroline
    Sheibani, Sarah
    My-Linh Tran-Minh
    Allez, Matthieu
    Shao, Ling
    GASTROENTEROLOGY, 2017, 152 (05) : S404 - S404
  • [3] A Search for the Best Utilization of Serum Infliximab (IFX) and Antibodies to Infliximab (ATI) Levels in Patients With Inflammatory Bowel Disease
    Sivananthan, Geethan
    Ladd, Antonio Mendoza
    Cohen, Joshua
    Feathers, Alexandra
    Schneider, Judy
    Swaminath, Arun
    Korelitz, Burton
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S492 - S492
  • [4] Antinuclear antibodies (ANA) in rheumatoid arthritis patients treated with infliximab
    Bonilla, G
    Gamero, F
    Fernandez-Melón, J
    Alvarez-Doformo, R
    Balsa, A
    Martín-Mola, E
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 433 - 433
  • [5] Anticardiolipin antibodies in patients with rheumatoid arthritis and spondyloarthropathies treated with infliximab
    Gómez-Puerta, JA
    Hernández, MV
    Reverter, JC
    Salvador, G
    Vázquez, I
    Graell, E
    Rodriguez-Cros, JR
    Gómez-Centeno, A
    Cañete, JD
    Sanmarti, R
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 253 - 253
  • [6] Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
    Aatke van der Maas
    Bart JF van den Bemt
    Gertjan Wolbink
    Frank HJ van den Hoogen
    Piet LCM van Riel
    Alfons A den Broeder
    BMC Musculoskeletal Disorders, 13
  • [7] Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
    van der Maas, Aatke
    van den Bemt, Bart J. F.
    Wolbink, Gertjan
    van den Hoogen, Frank H. J.
    van Riel, Piet L. C. M.
    den Broeder, Alfons A.
    BMC MUSCULOSKELETAL DISORDERS, 2012, 13
  • [8] SERUM INFLIXIMAB (IFX) CONCENTRATION AND ANTIBODIES (ATI) IN PEDIATRIC INFLAMMATORY BOWEL DISEASE (IBD)
    Lacorte, D.
    Retetangos, C.
    Silvestri, T.
    Stocco, G.
    Martelossi, S.
    Alvisi, P.
    DIGESTIVE AND LIVER DISEASE, 2016, 48 : E270 - E271
  • [9] Serum leptin inpatients with rheumatoid arthritis treated with infliximab
    Kopec, MM
    Wiecekl, A
    Kucharz, EJ
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 278 - 278
  • [10] Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide
    Bingham, SJ
    Buch, MH
    Kerr, MA
    Emery, P
    Barcelos, ATV
    ARTHRITIS AND RHEUMATISM, 2004, 50 (12): : 4072 - 4073
12345